165 related articles for article (PubMed ID: 33896649)
41. Report: workshop on mediastinal grey zone lymphoma.
Poppema S; Kluiver JL; Atayar C; van den Berg A; Rosenwald A; Hummel M; Lenze D; Lammert H; Stein H; Joos S; Barth T; Dyer M; Lichter P; Klein U; Cattoretti G; Gloghini A; Tu Y; Stolovitzky GA; Califano A; Carbone A; Dalla-Favera R; Melzner I; Bucur AJ; Brüderlein S; Dorsch K; Hasel C; Barth TF; Leithäuser F; Möller P
Eur J Haematol Suppl; 2005 Jul; (66):45-52. PubMed ID: 16007868
[TBL] [Abstract][Full Text] [Related]
42. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.
Mottok A; Hung SS; Chavez EA; Woolcock B; Telenius A; Chong LC; Meissner B; Nakamura H; Rushton C; Viganò E; Sarkozy C; Gascoyne RD; Connors JM; Ben-Neriah S; Mungall A; Marra MA; Siebert R; Scott DW; Savage KJ; Steidl C
Blood; 2019 Sep; 134(10):802-813. PubMed ID: 31292115
[TBL] [Abstract][Full Text] [Related]
43. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.
Savage KJ; Monti S; Kutok JL; Cattoretti G; Neuberg D; De Leval L; Kurtin P; Dal Cin P; Ladd C; Feuerhake F; Aguiar RC; Li S; Salles G; Berger F; Jing W; Pinkus GS; Habermann T; Dalla-Favera R; Harris NL; Aster JC; Golub TR; Shipp MA
Blood; 2003 Dec; 102(12):3871-9. PubMed ID: 12933571
[TBL] [Abstract][Full Text] [Related]
44. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
[TBL] [Abstract][Full Text] [Related]
45. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
[TBL] [Abstract][Full Text] [Related]
46. PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.
Volaric A; Bacchi CE; Gru AA
Am J Surg Pathol; 2020 Oct; 44(10):1353-1366. PubMed ID: 32649320
[TBL] [Abstract][Full Text] [Related]
47. Checkpoint blockade in lymphoma.
Armand P
Hematology Am Soc Hematol Educ Program; 2015; 2015():69-73. PubMed ID: 26637703
[TBL] [Abstract][Full Text] [Related]
48. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Green MR; Monti S; Rodig SJ; Juszczynski P; Currie T; O'Donnell E; Chapuy B; Takeyama K; Neuberg D; Golub TR; Kutok JL; Shipp MA
Blood; 2010 Oct; 116(17):3268-77. PubMed ID: 20628145
[TBL] [Abstract][Full Text] [Related]
49. Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas.
Singh K; Lezama LS; Kurzer J; Oak J; Schultz LM; Walkush A; Cheng TC; Chen EH; May WA; Chang C; Link MP; Advani RH; Suarez CJ; Natkunam Y
Am J Surg Pathol; 2023 Jan; 47(1):81-90. PubMed ID: 36001451
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.
Menter T; Bodmer-Haecki A; Dirnhofer S; Tzankov A
Hum Pathol; 2016 Aug; 54():17-24. PubMed ID: 27045512
[TBL] [Abstract][Full Text] [Related]
51. Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape.
Liu Y; Huang R; Liu L; Meng Y; Liu X
Cell Biochem Funct; 2020 Apr; 38(3):242-248. PubMed ID: 31709594
[TBL] [Abstract][Full Text] [Related]
52. Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma.
Song MK; Park BB; Uhm J
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884772
[TBL] [Abstract][Full Text] [Related]
53. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
54. [Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 27 cases].
Shi QY; Feng X; Chen H; Ma HH; Lu ZF; Shi QL; Zhou XJ; Shen Q
Zhonghua Bing Li Xue Za Zhi; 2017 Sep; 46(9):607-612. PubMed ID: 28910870
[No Abstract] [Full Text] [Related]
55.
Godfrey J; Tumuluru S; Bao R; Leukam M; Venkataraman G; Phillip J; Fitzpatrick C; McElherne J; MacNabb BW; Orlowski R; Smith SM; Kline J
Blood; 2019 May; 133(21):2279-2290. PubMed ID: 30910787
[TBL] [Abstract][Full Text] [Related]
56. The immune landscape and response to immune checkpoint blockade therapy in lymphoma.
Kline J; Godfrey J; Ansell SM
Blood; 2020 Feb; 135(8):523-533. PubMed ID: 31790142
[TBL] [Abstract][Full Text] [Related]
57. Distribution of malignant lymphomas in the anterior mediastinum: a single-institution study of 76 cases in Japan, 1997-2016.
Maeshima AM; Taniguchi H; Suzuki T; Yuda S; Toyoda K; Yamauchi N; Makita S; Fukuhara S; Munakata W; Maruyama D; Kobayashi Y; Tobinai K
Int J Hematol; 2017 Nov; 106(5):675-680. PubMed ID: 28921451
[TBL] [Abstract][Full Text] [Related]
58. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
Nayak L; Iwamoto FM; LaCasce A; Mukundan S; Roemer MGM; Chapuy B; Armand P; Rodig SJ; Shipp MA
Blood; 2017 Jun; 129(23):3071-3073. PubMed ID: 28356247
[TBL] [Abstract][Full Text] [Related]
59. Characterization of DLBCL with a PMBL gene expression signature.
Duns G; Viganò E; Ennishi D; Sarkozy C; Hung SS; Chavez E; Takata K; Rushton C; Jiang A; Ben-Neriah S; Woolcock BW; Slack GW; Hsi ED; Craig JW; Hilton LK; Shah SP; Farinha P; Mottok A; Gascoyne RD; Morin RD; Savage KJ; Scott DW; Steidl C
Blood; 2021 Jul; 138(2):136-148. PubMed ID: 33684939
[TBL] [Abstract][Full Text] [Related]
60. [PD-1 blockade therapy in lymphoid malignancies].
Nishikori M; Takaori-Kondo A
Rinsho Ketsueki; 2017; 58(10):2043-2049. PubMed ID: 28978847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
